1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

FDA gastrointestinal panel meeting scheduled for Salix's Xifaxan

 
• By Asher Mullard

A US FDA gastrointestinal drugs advisory meeting has been scheduled for February 23rd, 2010, to discuss Salix Pharmaceuticals' Xifaxan (rifaximin), which has been filed for maintenance of remission of hepatic encephalopathy.

A US FDA gastrointestinal drugs advisory meeting has been scheduled for February 23rd, 2010, to discuss Salix Pharmaceuticals' Xifaxan (rifaximin), which has been filed for maintenance of remission of hepatic encephalopathy.

The antibiotic has been available in the US since 2004, as Lumenax by Salix for the treatment of travellers' diarrhoea. It previously had a PDUFA date of December 24th, 2009,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

More from Therapeutic Category

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

GlycoEra’s Series B Cash Will Fund Efforts To Take On FcRn Inhibitor Class

 
• By Joseph Haas

GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.